The New York Times just published an article about a new malaria vaccine that is shown to work in infants less than a year old, the age group must vulnerable to vaccination risks. The vaccine, called RTS,S, or Mosquirix, has been shown to reduce the risk of catching malaria by 65% after three shots in 214 babies in Mozambique. Produced by GlaxoSmithKline, the vaccine could be ready for distribution by 2012 if it passes larger clinical trials set to start in seven countries next year. Glaxo has been working on the vaccine for over 20 years and anticipates spending up to $600 million on it by the time it reaches the market.
Here's a link to the article if you want to learn more: